| abstract |
Reracolyrant ((R)-(1- (4-fluorophenyl) -6-((1-methyl-1H-pyrazolo-4-yl) sulfonyl) -4,4a, 5,6,7,8-hexahydro-1H) -Pyrazolo [3,4-g] isoquinoline-4a-yl) (4- (trifluoromethyl) pyridin-2-yl) methanone with a disease suitable for treatment with a glucocorticoid receptor modulator (GRM) New formulations suitable for administration to a patient (including oral administration) are disclosed. Single dose forms include softgel capsules containing those formulations. Such softgel capsules are, for example, 25. These novel formulations and single dose forms may include Cushing syndrome, Cushing's disease, and relacolyrant formulations containing milligrams (mg), 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, or other amounts of relacolilanto. It can be used to treat diseases and disorders, including other disorders. |